It is made available under a CC-BY-NC-ND 4.0 International license .

1 Relationships between 25-Hydroxyvitamin D and Alpha-

2 synucleinopathies: A Mendelian Randomization Study

- 3 Fu-Jia Li¹, Ru-Lin Geng¹, Cheng Wen¹, Kai-Xun Huang¹, Dan-Yu Lin¹, Zhong-Gui
- 4 Li¹, Jie-Li Zhang¹, Chuan-Ying Xu², Wei Zhang², Jie Zu², Li-Guo Dong², Wen-Xin
- 5 Wang¹, Zhi-Jia Ruan¹, Pei-Xiao Yin², Chen-Yang Guan², Gui-Yun Cui^{2*}, En-Xiang

6 Tao^{1*} 6

- ⁷ ¹ Department of Neurology, The Eighth Affiliated Hospital, Sun Yat-Sen University,
- 8 Shenzhen, Guangdong, China
- ⁹ ² Department of Neurology, The Affiliated Hospital of Xuzhou Medical University,
- 10 Xuzhou, Jiangsu, China

- 12 Fu-Jia Li¹, Ru-Lin Geng¹, Cheng Wen¹, These authors contributed equally to this
- 13 work and share first authorship.
- 14
- 15 *** Corresponding Authors:**
- 16 Gui-Yun Cui

- 17 Department of Neurology, The Affiliated Hospital of Xuzhou Medical University
- 18 Xuzhou, Jiangsu, China
- 19 Tel: 8613852159170
- 20 Email: cuiguiyun-js@163.com
- 21
- 22 **En-Xiang Tao**
- 23 Department of Neurology, The Eighth Affiliated Hospital, Sun Yat-Sen University,
- 24 Shenzhen, Guangdong, China
- 25 Tel: 8613500034942
- 26 Email: taoex@mail.sysu.edu.cn
- 27
- 28 Word counts: 3,626
- 29
- 30

- 31
- 32

It is made available under a CC-BY-NC-ND 4.0 International license .

33 Abbreviations

- 34 25(OH)D: 25-hydroxyvitamin D
- 35 BWMR: Bayesian Weighted Mendelian randomization
- 36 CI: Confidence interval
- 37 cML-MA: Constrained maximum likelihood-model average
- 38 DLB: Dementia with Lewy bodies
- 39 GCI: Oligodendroglial cytoplasmic inclusion
- 40 IV: Instrumental variable
- 41 IVW: Inverse variance weighted
- 42 iRBD: Isolated rapid eye movement sleep behavior disorder
- 43 LD: Linkage disequilibrium
- 44 MR: Mendelian randomization
- 45 MR-PRESSO: Mendelian randomization pleiotropy residual sum and outlier
- 46 MR-RAPS: Mendelian randomization robust adjusted profile score
- 47 MSA: Multiple system atrophy

It is made available under a CC-BY-NC-ND 4.0 International license .

- 48 nSNPs: Number of instrumental variables
- 49 OPC: Impaired oligodendrocyte precursor cell
- 50 OR: Odds ratio
- 51 PD: Parkinson's disease
- 52 SNP: Single nucleotide polymorphism

It is made available under a CC-BY-NC-ND 4.0 International license .

63 Abstract

- 64 Background:
- 65 Alpha-synucleinopathies, including Parkinson's disease (PD), multiple system atrophy
- 66 (MSA), and dementia with Lewy bodies (DLB), are neurodegenerative diseases
- 67 characterized by abnormal aggregation of alpha-synuclein. Isolated REM sleep
- 68 behavior disorder (iRBD) is a prodromal stage of these disorders. While
- 69 25-hydroxyvitamin D (25[OH]D) has been linked to PD in previous studies, its causal
- role remains unclear, and its relationship with iRBD, MSA, and DLB is rarely
- 71 explored.
- 72 Objectives:
- 73 This study used Mendelian randomization (MR) to investigate the causal relationship
- the tween 25(OH)D and iRBD, PD, MSA, and DLB.
- 75 Methods:
- 76 GWAS data for 25(OH)D were sourced from the UK Biobank, and outcome data for
- PD were obtained from the latest FinnGen R12 database. Data for iRBD, PD onset
- age, PD clinical progression, MSA, and DLB were derived from a broader European
- 79 population. The study had two steps: univariable MR (UVMR) using genome-wide IV
- 80 selection as the primary analysis, with replication analyses using biological

It is made available under a CC-BY-NC-ND 4.0 International license .

- 81 function-based IV selection and sunlight exposure and vitamin D
- 82 supplementation-related factors as exposures. Multivariable MR (MVMR) was then
- 83 conducted to adjust for 13 covariates, testing the robustness of findings.
- 84 Results:
- 85 25(OH)D showed a significant protective effect on MSA across all UVMR (both
- 86 primary and replication) and MVMR analyses. It also exhibited a nominal protective
- 87 effect on PD in the Finnish population in primary UVMR analysis, but this was not
- 88 replicated. No associations were found between 25(OH)D and iRBD, PD onset age,
- 89 PD clinical progression, or DLB. Power analyses indicated insufficient sensitivity to
- 90 detect weak effects of 25(OH)D on iRBD and DLB.
- 91 Conclusions:
- 92 MR analysis supports a protective role of 25(OH)D against MSA. While nominally
- 93 protective for PD in the Finnish population, the effect was not robust. Weak effects on
- 94 iRBD and DLB cannot be excluded.

95 Keywords:

- 96 25-hydroxyvitamin D, Alpha-synucleinopathy, Parkinson's disease, Multiple system
- 97 atrophy, Dementia with Lewy bodies, Isolated REM sleep behavior disorder,
- 98 Mendelian randomization

It is made available under a CC-BY-NC-ND 4.0 International license .

99 Introduction

100	Alpha-synucleinopathies, encompassing Parkinson's disease (PD), multiple system
101	atrophy (MSA), and dementia with Lewy bodies (DLB), are neurodegenerative
102	disorders characterized by the misfolding and abnormal aggregation of
103	alpha-synuclein ¹ . These diseases result in progressive disability and mortality, with
104	overlapping yet distinct clinical manifestations. PD presents with characteristic motor
105	symptoms such as bradykinesia, resting tremor, and rigidity ² . MSA is defined by
106	severe autonomic dysfunction, often accompanied by parkinsonism or ataxia ³ . In
107	contrast, DLB is marked by fluctuating cognitive decline, visual hallucinations, and
108	parkinsonism ⁴ . Notably, isolated rapid eye movement sleep behavior disorder (iRBD),
109	a condition characterized by the loss of muscle atonia during REM sleep and the
110	presence of abnormal behaviors ⁵ , is recognized as a prodromal phase of
111	alpha-synucleinopathies ⁶ . Despite the substantial burden on patients and healthcare
112	systems, effective therapies for alpha-synucleinopathies remain scarce. Therefore,
113	identifying modifiable risk factors is critical for prevention and improving patient
114	outcomes.

115

Vitamin D, a fat-soluble steroid hormone, primarily exists in the body as
25-hydroxyvitamin D (25[OH]D). It has been suggested to protect against

It is made available under a	CC-BY-NC-ND 4.0 International license .
------------------------------	---

118	neurodegenerative diseases by maintaining calcium homeostasis, reducing oxidative
119	stress, inhibiting inflammation, and preventing the aggregation of misfolded proteins
120	(including alpha-synuclein) 7,8 , which are both involved in the pathogenesis of
121	alpha-synucleinopathies. However, whether 25(OH)D provides clinical protection
122	against alpha-synucleinopathies remains unclear.
123	
124	In PD, most cross-sectional studies report lower 25(OH)D levels in patients compared
125	to healthy controls ⁹⁻¹¹ , but it is debated whether this reduction contributes to disease
126	onset or results from disease progression. Immobility in PD could limit sunlight
127	exposure, as indicated by reduced outdoor time, thereby decreasing vitamin D
128	synthesis. Additionally, gastrointestinal dysfunction may impair absorption, both of
129	which could potentially lead to lower 25(OH)D levels. Although cohort studies reduce
130	reverse causation bias, their findings are inconsistent ¹²⁻¹⁴ . Additionally, clinical trials
131	on vitamin D supplementation have not consistently shown PD symptom
132	improvement ¹⁵⁻¹⁷ . Research on vitamin D in MSA ^{18,19} and DLB ²⁰ is even more limited,
133	hindered by small sample sizes and methodological issues, such as cross-sectional

- 134 designs and inadequate control for confounders like outdoor time and dietary vitamin
- 135 D intake. These limitations challenge the reliability and generalizability of existing

136 findings.

It is made available under a CC-BY-NC-ND 4.0 International license .

137

138	To develop effective interventions, identifying risk factors within the causal pathway
139	of the disease is essential. Mendelian randomization (MR) provides a robust method
140	for causal inference by minimizing confounding bias and reverse causation. The
141	limitations of the existing MR study, however, highlight the need for further research.
142	In 2017, Susanna C. Larsson and colleagues used MR to examine the relationship
143	between 25(OH)D and PD but found no causal link ²¹ . They partly attributed the
144	inconclusive results to the small effect size of 25(OH)D and the limited number of
145	instrumental variables (IVs), which reduced statistical power.
146	
147	With the availability of large genome-wide association study (GWAS) datasets and
148	advancements in MR methods, this study aims to comprehensively investigate the
149	relationships between 25(OH)D levels and iRBD, PD, age at PD onset, PD clinical

150 progression, MSA, and DLB.

151

152 Method

153 1. Study Design

It is made available under a CC-BY-NC-ND 4.0 International license .

154	Our stud	y consisted (of two step	ps. Step	one involved	univariable MR	(UVMR)
							```

- analysis, where we selected IVs across the whole genome to investigate the effects of
- 156 25(OH)D on the following outcomes: iRBD, PD, age at PD onset, progression of 21
- 157 clinical PD phenotypes, MSA, and DLB. This served as the primary analysis.
- 158 Outcomes showing nominal statistical significance with 25(OH)D (P < 0.05)
- 159 underwent further replication analysis, with biological function-based IV selection
- 160 and sunlight exposure and vitamin D supplementation-related factors as exposures. In
- 161 step two, outcomes with consistent results in primary and replication UVMR analyses
- 162 were further included in the MVMR analysis to adjust for covariates. The study
- strictly adhered to the three core assumptions²² of MR analysis and followed the
- 164 STROBE-MR guidelines²³ (**Table S2**).

165

#### 166 **2. Data Source**

We obtained summary-level GWAS statistics from recent large-scale studies of
European populations. To minimize sample overlap, exposure and outcome data were
derived from different cohorts. Ethical approvals were obtained from each
participating cohort, so no additional ethical approvals or informed consents were
required. The composition of GWAS data cohorts, the content of questionnaires used

It is made available under a CC-BY-NC-ND 4.0 International license .

- 172 to define clinical characteristics, the specific methods and kits used for laboratory
- 173 measurements, and the diagnostic criteria for diseases can be found in **Table S1**.

174

```
175 2.1 Exposures
```

- 176 As in previous studies  $^{24-26}$ , we used the most recent 25(OH)D GWAS dataset, which
- 177 is based on the UK Biobank population  $(n = 417,580)^{27}$ . Serum 25(OH)D
- 178 concentrations were measured using a chemiluminescence immunoassay (Diasorin
- 179 Liaison®), which covered 25(OH)D3 and 25(OH)D2. Individuals with total
- 180 concentrations outside the range of 10–375 nmol/L were excluded. The median, mean,
- and interquartile range of 25(OH)D concentrations were 47.9, 49.6, and 33.5–63.2
- 182 nmol/L, respectively.

- 184 Most vitamin D is synthesized in the skin through UV exposure, with only ~20%
- 185 obtained from dietary intake²⁸. Similar to previous observational studies^{11,29}, our study
- 186 also considered characteristics related to sunlight exposure and vitamin D
- 187 supplementation as exposure factors. The GWAS data for these characteristics were
- 188 derived from the UK Biobank and included variables such as time spend outdoors in
- 189 summer (n = 419,314) and winter (n = 364,465), skin color (n = 456,692), use of sun

It is made available under a CC-BY-NC-ND 4.0 International license .

- 190 protection (n = 459,416), use of vitamin D supplements (cases/controls =
- 191 17,879/442,472), and non-use of any vitamin or mineral supplements (cases/controls
- 192 = 144,656/315,695). These data were self-reported through touchscreen
- 193 questionnaires.

194

#### 195 2.2 Covariates

- 196 The "2024 Consensus Statement on Vitamin D Status Assessment and
- 197 Supplementation^{"30} highlighted key factors influencing vitamin D levels. If genetic
- 198 IVs for 25(OH)D are strongly associated with these factors, they may directly impact
- 199 outcomes via non-25(OH)D pathways, introducing horizontal pleiotropy and biasing
- 200 the results. To mitigate this, we identified 13 covariates, grouped them into three sets,
- and sequentially incorporated them into MVMR analyses to minimize horizontal
- 202 pleiotropy and strengthen the reliability of our causal inference. The covariate data
- 203 were mainly derived from the UK Biobank. Set 1 included lifestyle and
- 204 socioeconomic factors: body mass index, smoking initiation, alcohol intake frequency,
- 205 levels of moderate-to-vigorous physical activity, and years of education. Set 2
- 206 comprised vitamin D metabolism-related markers: alanine aminotransferase,
- 207 creatinine, and parathyroid hormone levels. Set 3 included chronic health conditions:

It is made available under a CC-BY-NC-ND 4.0 International license .

208 hypertension, type 2 diabetes, atherosclerotic cardiovascular diseases, stroke, and

209 gastrointestinal or abdominal diseases.

210

#### 211 **2.3 Outcomes**

212	To avoid sam	ole overlap,	given that	the exposure	data in th	is study we	ere sourced fr	rom
-----	--------------	--------------	------------	--------------	------------	-------------	----------------	-----

- 213 the UK Biobank, we did not use datasets curated by Mike A. Nalls (December 2019) 31
- or Jonggeol Jeffrey Kim (January 2024)³². Instead, we used the latest PD GWAS data

215 from the FinnGen R12 database (https://r12.finngen.fi/, November 2024), which

216 included 5,861 cases and 494,487 controls. PD diagnoses were based on ICD-10

217 (G20), ICD-9 (3320A), and ICD-8 (34200) codes. Similarly, Tao Wang et al.

218 followed the same data selection strategy under similar circumstances³³. The PD

age-at-onset dataset was obtained from the International Parkinson's Disease

220 Genomics Consortium³⁴. Age at onset was defined based on patient-reported initial

221 parkinsonian motor symptoms, or, if unavailable, the age of diagnosis was used as a

222 proxy. The datasets on PD clinical progression included 12 longitudinal cohorts of PD

- 223 patients recruited from North America, Europe, and Australia³⁵. These datasets
- included 21 clinical features of disease progression, covering changes in staging,
- 225 worsening motor symptoms, reduced daily functioning, aggravated non-motor
- symptoms, cognitive decline, new motor complications, depression, impaired smell,

It is made available under a CC-BY-NC-ND 4.0 International license .

227	increased constipation, and sleep disturbances. The iRBD GWAS data, aggregated by
228	Lynne Krohn's team in December 2022, included 1,061 cases and 8,386 controls from
229	cohorts in France, Canada, Italy, the UK, and other European countries ³⁶ . Cases were
230	identified by the International RBD Study Group, diagnosed according to the
231	International Classification of Sleep Disorders (2nd or 3rd Edition), and confirmed via
232	video-polysomnography. MSA GWAS data, aggregated by Ruth Chia's team in July
233	2024, included 888 cases and 7,128 controls recruited from 20 centers across North
234	America and Europe ³⁷ . Cases were diagnosed as clinically probable or pathologically
235	confirmed using the Gilman consensus criteria. DLB GWAS data, also aggregated by
236	Ruth Chia's team in February 2021, comprised 2,591 cases and 4,027 controls ³⁸ .
237	Participants were recruited from 44 centers in Europe and North America, with
238	controls drawn from the Wellderly cohort and the National Institute on Aging. DLB
239	cases were either autopsy-confirmed or clinically probable.

240

#### 241 **3. Genetic Instrument Selection**

242 In this study, IVs were selected using two approaches. First, genome-wide IV

243 selection: single nucleotide polymorphisms (SNPs) significantly associated with the

244 exposure (P <  $5 \times 10$   $\square$  ) across the whole genome were chosen. If this threshold

245 yielded insufficient IVs, a more lenient threshold ( $P < 5 \times 10 \square \square$ ) was applied,

It is made available under a CC-BY-NC-ND 4.0 International license .

246	selecting IVs for il	RBD. PD age at onset	, progression of PD	symptoms, MSA, DLB.
		,	, , , , , , , , , , , , , , , , , , , ,	

- and vitamin D supplementation. Second, biological function-based IV selection: IVs
- 248 were selected from genes involved in vitamin D metabolism, including GC, CYP2R1,
- 249 DHCR7, and CYP24A1^{39,40}.

250

- 251 The R² value was used to assess the proportion of variance in exposure explained by
- each SNP, while the F-statistic ensured instrument strength (retaining only SNPs with
- 253 F > 10). SNPs in linkage disequilibrium (r² > 0.001, window size 10,000 kb) or with
- 254 effect allele frequencies below 0.01 were excluded. To meet MR independence
- assumptions, SNPs directly associated with the outcome were identified and excluded
- 256 according to the LDtrait database (<u>https://ldlink.nih.gov/?tab=ldtrait</u>).

257

#### 258 **4. Mendelian Randomization**

- 259 For the UVMR analyses, we used multiple analytical models. The inverse variance
- 260 weighted (IVW)⁴¹ method served as the primary model due to its high statistical
- 261 power when all instrumental variables are valid, though it is sensitive to heterogeneity
- and pleiotropy. To enhance robustness, we applied five secondary models:
- 263 MR-Egger⁴² and weighted median⁴³ methods, which provide reliable estimates in the

It is made available under a CC-BY-NC-ND 4.0 International license .

264	presence of pleiotropy or invalid instruments, albeit with lower power; the constrained
265	maximum likelihood-model average (cML-MA) ⁴⁴ method, robust against pleiotropy;
266	the robust adjusted profile score (MR-RAPS) ⁴⁵ method, effective for weak
267	instruments; and Bayesian weighted MR (BWMR) ⁴⁶ , which uses Bayesian weighting
268	to address pleiotropy and accounts for polygenicity, making it suitable for analyzing
269	complex traits or diseases. These methods complemented each other and contributed
270	to the reliability and robustness of the results. MR results were reported as odds ratios
271	(OR) with 95% confidence intervals (CI), representing the effect of a genetically
272	determined unit change in exposure on outcome risk. For continuous exposures, the
273	OR reflects the change in risk per one standard deviation increase; for binary
274	exposures, it represents the risk ratio between exposed and non-exposed groups.
275	
276	In the UVMR analyses, several sensitivity analyses were performed to ensure
277	robustness: (1) Results from genome-wide IV selection served as the primary UVMR
278	analysis, while replication analyses used biological function-based IV selection and
279	exposures such as sunlight exposure and vitamin D supplementation for mutual
280	validation; (2) Effect estimates were obtained using one primary model and five
281	secondary models suited to different assumptions; (3) Cochran's Q-statistic was

283 pleiotropy was assessed using the MR-Egger intercept p-value⁴² and the Mendelian

It is made available under a CC-BY-NC-ND 4.0 International license .

284	Randomization Pleiotropy RESidual Sum and Outlier (MR-PRESSO) global test ⁴⁷ ; (5)
285	Outliers among IVs were identified using MR-PRESSO and MR-Radial (Radial-IVW
286	and Radial-Egger tests, with $P < 0.05$ indicating outliers), and MR analyses were
287	repeated after removing identified outliers; (6) Leave-one-out analyses were
288	conducted to determine whether the results were driven by specific SNPs; (7) Finally,
289	the tool https://shiny.cnsgenomics.com/mRnd/ was used to calculate the minimum
290	detectable causal effect size at 80% statistical power in the MR analyses ⁴⁸ .
291	
292	To reduce bias from reverse causality, we adopted the following strategies: (1)
293	Excluding IVs significantly associated with the outcome; (2) Testing the causal
294	direction using the Steiger test ⁴⁹ ; and (3) Conducting reverse MR analyses.

295

296	In the MVMR analyses, causal effects were estimated using the MVMR-IVW, and
297	MVMR-Egger methods, with horizontal pleiotropy evaluated based on whether the
298	MR-Egger intercept significantly deviated from zero. When no pleiotropy was
299	detected, the MVMR-IVW method was used as the primary estimator; if pleiotropy
300	was present, the results primarily relied on the MVMR-Egger method ⁴² .

It is made available under a CC-BY-NC-ND 4.0 International license .

- 302 All analyses were two-sided tests performed using R version 4.4.1. Relevant R
- 303 packages included TwoSampleMR, MendelianRandomization, MR-PRESSO,
- 304 RadialMR, MR.RAPS, MRcML, and BWMR.

305

#### 306 **Results**

#### 307 1. Primary UVMR analysis results

- 308 After quality control and removing SNPs in linkage disequilibrium, 115 SNPs
- 309 strongly associated with 25(OH)D were retained as candidate IVs (Table S3). A
- 310 search on the LDtrait platform identified six SNPs directly associated with
- 311 alpha-synucleinopathies (Table S4), which were excluded. Among the remaining 109
- 312 SNPs, 104, 104, 97, 97, and 98 were successfully harmonized with the datasets for
- 313 iRBD, PD, age at onset of PD, MSA, and DLB, respectively. These SNPs explained
- approximately 4.28%-4.42% of the variance in 25(OH)D levels, and all F-statistics
- 315 exceeded 10, confirming that the MR results were not affected by weak instruments
- 316 (**Table 1**).

#### 317

318 UVMR analysis showed a significant protective effect of higher 25(OH)D levels on
319 MSA (OR [95% CI]: 0.598 [0.421, 0.851], P = 0.004, P_FDR = 0.021, Figure 2).

It is made available under a CC-BY-NC-ND 4.0 International license .

320	This finding was supported by the primary analysis model (IVW) and four secondary
321	models (MR Egger, Weighted median, MR-RAPS, and BWMR), with the cML-MA
322	model showing consistent effect direction despite not reaching statistical significance.
323	MR-PRESSO identified no significant outliers among the 97 instrumental variables,
324	while MR-Radial detected 1 potential outlier (Table S5). Reanalysis excluding this
325	outlier produced robust results (Table S6). Steiger directionality tests and reverse MR
326	(Table S9, 10) supported the causal direction, and Cochran's Q test indicated no
327	heterogeneity. MR-Egger regression and the MR-PRESSO global test showed no
328	evidence of horizontal pleiotropy (Table S7). Leave-one-out analysis confirmed that
329	results were not driven by individual SNPs (Table S8).
330	

331 MR analysis also suggested a nominal protective effect of higher 25(OH)D levels on

332 PD (OR [95% CI]: 0.867 [0.758, 0.991], P = 0.036, P_FDR = 0.091, Figure 2),

333 supported by the IVW, MR-RAPS, and BWMR models, with consistent effect

- directions across all six models. MR-PRESSO detected no significant outliers among
- the 104 instrumental variables, while MR-Radial identified 7 potential outliers (Table
- 336 S5). Reanalysis excluding these outliers showed robust results (Table S6). Sensitivity
- analyses confirmed the findings were consistent in direction and unaffected by
- 338 heterogeneity or horizontal pleiotropy (**Table S7-10**).

It is made available under a CC-BY-NC-ND 4.0 International license .

340	However, UVMR analysis did not provide evidence of an effect of 25(OH)D levels on
341	age at onset of PD, PD clinical progression (Table S6), or the risk of iRBD and DLB
342	(Figure 2). These results remained robust in sensitivity analyses (Table S7-10).
343	Statistical power calculations suggested that UVMR analysis might not have been
344	sufficient to detect weaker effects of 25(OH)D on iRBD and DLB (Table 1).
345	
346	2. Replication UVMR analysis results
347	We selected eight SNPs from four key genes involved in vitamin D metabolism as
347 348	We selected eight SNPs from four key genes involved in vitamin D metabolism as IVs (GC: rs111978466, rs1352846, rs62318873; DHCR7: rs2276360, rs36037728;
<ul><li>347</li><li>348</li><li>349</li></ul>	We selected eight SNPs from four key genes involved in vitamin D metabolism as IVs (GC: rs111978466, rs1352846, rs62318873; DHCR7: rs2276360, rs36037728; CYP2R1: rs116970203; CYP24A1: rs8121940, rs8123293, <b>Table S11</b> ) and
<ul><li>347</li><li>348</li><li>349</li><li>350</li></ul>	We selected eight SNPs from four key genes involved in vitamin D metabolism as IVs (GC: rs111978466, rs1352846, rs62318873; DHCR7: rs2276360, rs36037728; CYP2R1: rs116970203; CYP24A1: rs8121940, rs8123293, <b>Table S11</b> ) and conducted UVMR analysis again. The results confirmed that 25(OH)D remains a
<ul><li>347</li><li>348</li><li>349</li><li>350</li><li>351</li></ul>	We selected eight SNPs from four key genes involved in vitamin D metabolism as IVs (GC: rs111978466, rs1352846, rs62318873; DHCR7: rs2276360, rs36037728; CYP2R1: rs116970203; CYP24A1: rs8121940, rs8123293, <b>Table S11</b> ) and conducted UVMR analysis again. The results confirmed that 25(OH)D remains a protective factor for MSA (OR [95% CI]: 0.562 [0.366, 0.863], P = 0.008, <b>Figure 3A</b> ).
<ul> <li>347</li> <li>348</li> <li>349</li> <li>350</li> <li>351</li> <li>352</li> </ul>	We selected eight SNPs from four key genes involved in vitamin D metabolism as IVs (GC: rs111978466, rs1352846, rs62318873; DHCR7: rs2276360, rs36037728; CYP2R1: rs116970203; CYP24A1: rs8121940, rs8123293, <b>Table S11</b> ) and conducted UVMR analysis again. The results confirmed that 25(OH)D remains a protective factor for MSA (OR [95% CI]: 0.562 [0.366, 0.863], $P = 0.008$ , <b>Figure 3A</b> ). However, its effect on PD was no longer significant. We also examined the
<ul> <li>347</li> <li>348</li> <li>349</li> <li>350</li> <li>351</li> <li>352</li> <li>353</li> </ul>	We selected eight SNPs from four key genes involved in vitamin D metabolism as IVs (GC: rs111978466, rs1352846, rs62318873; DHCR7: rs2276360, rs36037728; CYP2R1: rs116970203; CYP24A1: rs8121940, rs8123293, <b>Table S11</b> ) and conducted UVMR analysis again. The results confirmed that 25(OH)D remains a protective factor for MSA (OR [95% CI]: 0.562 [0.366, 0.863], $P = 0.008$ , <b>Figure 3A</b> ). However, its effect on PD was no longer significant. We also examined the relationships between sunlight exposure, vitamin D supplementation-related factors,

- 355 identified as risk factors for MSA, while vitamin D supplementation had a protective
- 356 effect on MSA (Figure 3B, Table S12). No evidence was found to support an

It is made available under a CC-BY-NC-ND 4.0 International license .

- 357 influence of sunlight exposure or vitamin D supplementation on PD risk. These
- 358 findings remained robust in sensitivity analyses (Table S13).

359

#### 360 3. MVMR analysis results

- 361 After adjusting for lifestyle and socioeconomic factors (body mass index, smoking,
- 362 alcohol intake frequency, moderate-to-vigorous physical activity levels, and years of
- 363 education), vitamin D metabolism-related markers (alanine aminotransferase,
- 364 creatinine, and parathyroid hormone levels), and chronic health conditions
- 365 (hypertension, type 2 diabetes, atherosclerotic cardiovascular disease, stroke, and
- 366 gastrointestinal or abdominal disease), the protective effects of 25(OH)D on MSA
- 367 remained significant (Figure 4). Sensitivity analyses suggested that some results were
- 368 mildly influenced by heterogeneity (**Table S14**), likely due to the large number of
- 369 instrumental variables used. None of the results were affected by horizontal pleiotropy
- 370 (**Table S14**).
- 371

### 372 Discussion

This is the first MR study comprehensively exploring the relationship between serum
25(OH)D levels and alpha-synucleinopathies. Our findings provide evidence for the

it is made	avaliable und		4.0 memalior	la license.

375	protective effect of 25	(OH)D on MSA,	which remained	l robust across	primary and
-----	-------------------------	---------------	----------------	-----------------	-------------

- 376 replication UVMR analyses and after adjusting for 13 covariates in MVMR analysis.
- 377 Additionally, 25(OH)D showed a nominal protective effect on PD in the Finnish
- 378 population, though this lacked sufficient robustness. The possibility of a weak effect
- 379 on iRBD or DLB cannot be ruled out.

380

#### 381 1. Declined 25(OH)D Levels in PD: Risk Factor or Consequence?

202	י חח	1 4	1	1. 1	1 / 1	1 /
3X/	PLI IS THE SECOND	i most common r	ieurodegenerativ	a disorder a	nd the most	nrevalent
504			iculouczencian v	c uisoiuci a	nu uic most	provatont
			0			1

- $\alpha$ -synucleinopathy. The relationship between 25(OH)D and PD remains controversial.
- 384 Most cross-sectional studies have reported significantly lower 25(OH)D levels in PD
- 385 patients compared to controls⁹⁻¹¹. However, this decrease may reflect disease
- 386 progression rather than causality, potentially influenced by reduced sunlight exposure
- 387 due to impaired mobility or vitamin D malabsorption caused by gastrointestinal
- 388 symptoms. In contrast, cohort studies are less affected by reverse causation but yield
- 389 inconsistent findings. While studies in Finnish and UK Biobank cohorts support a
- 390 protective role of 25(OH)D against  $PD^{12,13}$ , research from the United States found no
- 391 significant association¹⁴. Variability in genetic background, geographic factors, and
- 392 behavioral differences across cohorts likely contributes to these discrepancies.

It is made available under a CC-BY-NC-ND 4.0 International license .

394	MR analysis offers a robust approach to address confounding and reverse causation
395	compared to observational studies. In 2017, Susanna C. Larsson utilized small GWAS
396	data in an MR analysis of 25(OH)D and PD but found no significant association ²¹ .
397	Using larger GWAS datasets, our study identified a nominal protective effect of
398	25(OH)D against PD in the Finnish population. However, this finding lacked
399	robustness in replication analyses. We speculate that the protective effect of 25(OH)D
400	on PD may be modest, and the limited statistical power of replication analyses might
401	have hindered the detection of such a weak effect, which could also explain the null
402	results in Larsson's study.
403	
404	Notably, a 2011 cohort study reported that 25(OH)D levels did not decline with PD
405	progression ⁵⁰ . Similarly, our reverse MR analysis showed that PD status does not
406	significantly affect 25(OH)D levels. Furthermore, advancing Hoehn and Yahr stages,
407	worsening motor symptoms, and increased severity of constipation were not
408	associated with changes in 25(OH)D levels. These findings provide additional
409	evidence supporting the hypothesis that reduced 25(OH)D levels are a risk factor for
410	PD rather than a consequence of disease progression.

411

### 412 2. 25(OH)D and MSA: Present Evidence and Potential Mechanisms

It is made available under a CC-BY-NC-ND 4.0 International license .

413	MSA is at least ten times less prevalent than PD but progresses more rapidly, often
414	causing severe disability within 5-6 years and death within 10 years of symptom
415	onset ³ . Due to its rarity, only two cross-sectional studies have investigated the
416	relationship between 25(OH)D levels and MSA, both reporting significantly lower
417	levels in MSA patients compared to controls ^{18,19} . However, these studies did not
418	adjust for confounders, limiting their reliability. Our MR analysis supports a causal
419	relationship between lower 25(OH)D levels and increased MSA risk. This conclusion
420	was robust across primary and replication UVMR analyses and remained consistent
421	after comprehensive covariate adjustment using MVMR. The MR findings align with
422	trends observed in previous studies but should be interpreted cautiously due to
423	population differences. Observational studies were predominantly conducted in Asian
424	cohorts, while our MR analysis used European data. Notably, genetic differences and
425	subtype distributions (MSA-P vs. MSA-C) between European and Asian MSA
426	patients ³ may influence results. Prospective observational studies in European
427	populations are needed to validate these findings.

428

429 Vitamin D can cross the blood-brain barrier⁵¹, and its receptors are widely expressed
430 in neurons and glial cells⁵², providing a biological basis for its potential role in MSA.
431 Research suggests that vitamin D exerts neuroprotective effects in neurodegenerative
432 diseases by suppressing immune-inflammatory responses, reducing oxidative stress,

It is made available under a CC-BY-NC-ND 4.0 International license .

433	enhancing autophagy, and promoting neurotrophic factor expression ^{7,53} . These
434	mechanisms may also explain its protective role in MSA, which shares overlapping
435	pathogenic pathways with other neurodegenerative disorders ^{3,54} . Additionally,
436	25(OH)D may also confer protective effects against MSA through distinct
437	mechanisms. MSA is characterized by oligodendroglial cytoplasmic inclusions (GCIs)
438	rich in aggregated $\alpha$ -synuclein, along with extensive myelin degeneration and
439	oligodendrocyte dysfunction (impaired oligodendrocyte precursor cell [OPC]
440	maturation, remyelination defects, and reduced neuroprotective functions) ⁵⁴⁻⁵⁸ . In
441	vitro studies demonstrate that vitamin D reduces $\alpha$ -synuclein oligomer aggregation
442	and associated neurocytotoxicity in neurons ⁸ , though its potential effect on
443	$\alpha$ -synuclein deposition in oligodendrocytes remains unclear. Additionally, vitamin D
444	promotes remyelination and neurorepair by enhancing OPC differentiation and
445	creating a protective microenvironment ⁵⁹⁻⁶² , suggesting its therapeutic potential in
446	MSA.

447

#### 448 **3.** Clinical Implications

(1) MSA progresses rapidly, with no disease-modifying treatments or effective
symptomatic management. Reducing its incidence is essential to alleviating the
disease burden. While risk factors for MSA were previously unknown, our study is

It is made available under a CC-BY-NC-ND 4.0 International license .

452	the first to identify 25(OH)D as a protective factor. Given the high prevalence of
453	vitamin D deficiency ⁶³ , widespread vitamin D supplementation may have the
454	potential to significantly reduce MSA incidence. (2) Our findings highlight the need
455	for multicenter prospective studies to confirm the protective effect of 25(OH)D on
456	MSA. Further exploration is warranted to determine if this effect extends to patients
457	with iRBD and early autonomic dysfunction, prodromal stages of $MSA^{6}$ . (3) Our
458	study provides additional evidence that reduced 25(OH)D levels are a risk factor for
459	PD rather than a consequence of disease progression, requiring further follow-up
460	studies.

461

### 462 **4.** Limitations

463	(1) Our study population was European, which may limit the generalizability of the
464	findings. While we identified a protective effect of 25(OH)D against MSA, previous
465	supporting observational studies were conducted in Asian populations. Future
466	observational studies in European populations are needed to validate this conclusion.
467	(2) The limited sample size prevented us from determining whether the lack of
468	associations between 25(OH)D, iRBD risk, PD progression, and DLB risk reflects
469	insufficient statistical power or a true absence of association. Larger GWAS datasets
470	are needed for future MR analyses. (3) Due to data constraints, we could not assess

It is made available under a CC-BY-NC-ND 4.0 International license .

- 471 whether 25(OH)D influences MSA risk in patients with iRBD or early autonomic
- 472 dysfunction, nor its effects on MSA progression. These areas warrant further study.

473

- 474 **5.** Conclusions
- 475 In summary, our study identifies a protective role of 25(OH)D against MSA.
- 476 Although 25(OH)D showed a nominal protective effect on PD in the Finnish
- 477 population, the result lacked robustness. Potential weak effects on iRBD and DLB
- 478 cannot be excluded.

479

#### 480 Acknowledgement

- 481 FJL, RLG, and CW designed research; FJL, RLG, CW, GYC, EXT, and the other
- 482 authors (KXH, DYL, ZGL, JLZ, CYX, WZ, JZ, LGD, WXW, ZJR, PXY, CYG)
- 483 conducted research; GYC, EXT, and the other authors (KXH, DYL, ZGL, JLZ, CYX,
- 484 WZ, JZ, LGD, WXW, ZJR, PXY, CYG) provided essential materials; FJL, RLG, and
- 485 CW analyzed data; and FJL, RLG, and CW wrote the paper. GYC and EXT had
- 486 primary responsibility for final content. All authors read and approved the final
- 487 manuscript.

It is made available under a CC-BY-NC-ND 4.0 International license .

### 489 **Conflict of Interest**

490 The authors have no conflicts of interest relevant to the content of this article.

491

#### 492 Funding

- 493 This study was funded by Shenzhen Science and Technology Program
- 494 (JCYJ20220818102206014), National Natural Science Foundation of China
- 495 (82271454), the Futian Healthcare Research Project (FTWS2022010), the District
- 496 Key Specialty Funds / Department of Neurology (QZDZK-202410), and the Hospital
- 497 Key Discipline Funds / Department of Neurology (YZDXKJF-202017).

498

#### 499 Data Sharing

- 500 The GWAS data sources used in this study are detailed in the Methods section and
- 501 Table S1. Code book, and analytic code will be made available upon request pending.

502

503

It is made available under a CC-BY-NC-ND 4.0 International license .

### 505 **Reference**

- 506 1. Spillantini MG, Goedert M. The alpha-synucleinopathies: Parkinson's disease,
- 507 dementia with Lewy bodies, and multiple system atrophy. Annals of the New York
- 508 Academy of Sciences. 2000;920:16-27. doi:10.1111/j.1749-6632.2000.tb06900.x
- 509 2. Poewe W, Seppi K, Tanner CM, et al. Parkinson disease. *Nature reviews Disease*510 *primers*. Mar 23 2017;3:17013. doi:10.1038/nrdp.2017.13
- 511 3. Poewe W, Stankovic I, Halliday G, et al. Multiple system atrophy. *Nature*
- 512 reviews Disease primers. Aug 25 2022;8(1):56. doi:10.1038/s41572-022-00382-6
- 513 4. Prasad S, Katta MR, Abhishek S, et al. Recent advances in Lewy body dementia:
- 514 A comprehensive review. *Disease-a-month : DM*. May 2023;69(5):101441.
- 515 doi:10.1016/j.disamonth.2022.101441
- 516 5. Dauvilliers Y, Schenck CH, Postuma RB, et al. REM sleep behaviour disorder.
- 517 *Nature reviews Disease primers*. Aug 30 2018;4(1):19.
- 518 doi:10.1038/s41572-018-0016-5
- 519 6. Wenning GK, Stankovic I, Vignatelli L, et al. The Movement Disorder Society
- 520 Criteria for the Diagnosis of Multiple System Atrophy. Movement disorders : official
- 521 *journal of the Movement Disorder Society*. Jun 2022;37(6):1131-1148.
- 522 doi:10.1002/mds.29005
- 523 7. Wang W, Li Y, Meng X. Vitamin D and neurodegenerative diseases. *Heliyon*. Jan
  524 2023;9(1):e12877. doi:10.1016/j.heliyon.2023.e12877
- 525 8. Zhang Y, Ji W, Zhang S, et al. Vitamin D Inhibits the Early Aggregation of
- 526 α-Synuclein and Modulates Exocytosis Revealed by Electrochemical Measurements.
- 527 Angewandte Chemie (International ed in English). Jan 3 2022;61(1):e202111853.
  528 doi:10.1002/anie.202111853
- 529 9. Suzuki M, Yoshioka M, Hashimoto M, et al. 25-hydroxyvitamin D, vitamin D
- 530 receptor gene polymorphisms, and severity of Parkinson's disease. *Movement*
- *disorders : official journal of the Movement Disorder Society.* Feb 2012;27(2):264-71.
- 532 doi:10.1002/mds.24016
- 533 10. Wang L, Evatt ML, Maldonado LG, et al. Vitamin D from different sources is
- 534 inversely associated with Parkinson disease. *Movement disorders : official journal of*
- 535 the Movement Disorder Society. Apr 2015;30(4):560-6. doi:10.1002/mds.26117
- 536 11. Zhou Z, Zhou R, Zhang Z, Li K. The Association Between Vitamin D Status,
- 537 Vitamin D Supplementation, Sunlight Exposure, and Parkinson's Disease: A
- 538 Systematic Review and Meta-Analysis. Medical science monitor : international

- *medical journal of experimental and clinical research.* Jan 23 2019;25:666-674.
  doi:10.12659/msm.912840
- 541 12. Knekt P, Kilkkinen A, Rissanen H, Marniemi J, Sääksjärvi K, Heliövaara M.
- 542 Serum vitamin D and the risk of Parkinson disease. *Archives of neurology*. Jul
- 543 2010;67(7):808-11. doi:10.1001/archneurol.2010.120
- 544 13. Veronese N, Nova A, Fazia T, et al. Contribution of Nutritional, Lifestyle, and
- 545 Metabolic Risk Factors to Parkinson's Disease. Movement disorders : official journal
- 546 of the Movement Disorder Society. Jul 2024;39(7):1203-1212.
- 547 doi:10.1002/mds.29778
- 548 14. Shrestha S, Lutsey PL, Alonso A, Huang X, Mosley TH, Jr., Chen H. Serum
- 549 25-hydroxyvitamin D concentrations in Mid-adulthood and Parkinson's disease risk.
- 550 Movement disorders : official journal of the Movement Disorder Society. Jul
- 551 2016;31(7):972-8. doi:10.1002/mds.26573
- 552 15. Suzuki M, Yoshioka M, Hashimoto M, et al. Randomized, double-blind,
- 553 placebo-controlled trial of vitamin D supplementation in Parkinson disease. The
- 554 American journal of clinical nutrition. May 2013;97(5):1004-13.
- 555 doi:10.3945/ajcn.112.051664
- 556 16. Bytowska ZK, Korewo-Labelle D, Berezka P, et al. Effect of 12-Week
- 557 BMI-Based Vitamin D(3) Supplementation in Parkinson's Disease with Deep Brain
- 558 Stimulation on Physical Performance, Inflammation, and Vitamin D Metabolites.
- 559 International journal of molecular sciences. Jun 15
- 560 2023;24(12)doi:10.3390/ijms241210200
- 561 17. Hiller AL, Murchison CF, Lobb BM, O'Connor S, O'Connor M, Quinn JF. A
- 562 randomized, controlled pilot study of the effects of vitamin D supplementation on
- balance in Parkinson's disease: Does age matter? *PloS one*. 2018;13(9):e0203637.
- 564 doi:10.1371/journal.pone.0203637
- 565 18. Guo Y, Zhuang XD, Xian WB, et al. Serum Klotho, vitamin D, and homocysteine
- 566 in combination predict the outcomes of Chinese patients with multiple system
- trophy. CNS neuroscience & therapeutics. Aug 2017;23(8):657-666.
- 568 doi:10.1111/cns.12711
- 569 19. Ogura H, Hatip-Al-Khatib I, Suenaga M, et al. Circulatory 25(OH)D and
- 570 1,25(OH)(2)D as differential biomarkers between multiple system atrophy and
- 571 Parkinson's disease patients. *eNeurologicalSci*. Dec 2021;25:100369.
- 572 doi:10.1016/j.ensci.2021.100369
- 573 20. Janse A, van de Rest O, de Groot L, Witkamp RF. The Association of Vitamin D
- 574 Status with Mild Cognitive Impairment and Dementia Subtypes: A Cross-Sectional

- 575 Analysis in Dutch Geriatric Outpatients. Journal of Alzheimer's disease : JAD.
- 576 2023;91(4):1359-1369. doi:10.3233/jad-220732
- 577 21. Larsson SC, Singleton AB, Nalls MA, Richards JB. No clear support for a role
- 578 for vitamin D in Parkinson's disease: A Mendelian randomization study. Movement
- 579 disorders : official journal of the Movement Disorder Society. Aug
- 580 2017;32(8):1249-1252. doi:10.1002/mds.27069
- 581 22. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation
- 582 studies: a guide, glossary, and checklist for clinicians. *BMJ (Clinical research ed)*. Jul
- 583 12 2018;362:k601. doi:10.1136/bmj.k601
- 584 23. Skrivankova VW, Richmond RC, Woolf BAR, et al. Strengthening the reporting
- 585 of observational studies in epidemiology using mendelian randomisation
- 586 (STROBE-MR): explanation and elaboration. *BMJ* (*Clinical research ed*). Oct 26
- 587 2021;375:n2233. doi:10.1136/bmj.n2233
- 588 24. Konzok J, Baumeister SE, Winkler TW, Leitzmann MF, Baurecht H. Effect of
- 589 25-hydroxyvitamin D levels on the internalising dimension as a transdiagnostic risk
- 590 factor: Mendelian randomisation study. The British journal of psychiatry : the journal
- 591 of mental science. Jun 2023;222(6):257-263. doi:10.1192/bjp.2023.32
- 592 25. Lee KJ, Kim H, Lee SJ, et al. Causal Effect of the 25-Hydroxyvitamin D
- 593 Concentration on Cerebral Small Vessel Disease: A Mendelian Randomization Study.
- 594 *Stroke*. Sep 2023;54(9):2338-2346. doi:10.1161/strokeaha.123.042980
- 595 26. Zhang X, He Y, Li X, et al. Circulating 25-hydroxyvitamin D and survival
- 596 outcomes of colorectal cancer: evidence from population-based prospective cohorts
- 597 and Mendelian randomisation. British journal of cancer. May
- 598 2024;130(9):1585-1591. doi:10.1038/s41416-024-02643-5
- 599 27. Revez JA, Lin T, Qiao Z, et al. Genome-wide association study identifies 143 loci
- associated with 25 hydroxyvitamin D concentration. *Nature communications*. Apr 2
- 601 2020;11(1):1647. doi:10.1038/s41467-020-15421-7
- 602 28. Landel V, Annweiler C, Millet P, Morello M, Féron F. Vitamin D, Cognition and
- 603 Alzheimer's Disease: The Therapeutic Benefit is in the D-Tails. *Journal of*
- 604 Alzheimer's disease : JAD. May 11 2016;53(2):419-44. doi:10.3233/jad-150943
- 605 29. Hu L, Shi Y, Zou X, et al. Association of time spent outdoors with the risk of
- 606 Parkinson's disease: a prospective cohort study of 329,359 participants. *BMC*
- 607 *neurology*. Jan 2 2024;24(1):10. doi:10.1186/s12883-023-03499-7
- 608 30. Giustina A, Bilezikian JP, Adler RA, et al. Consensus Statement on Vitamin D
- 609 Status Assessment and Supplementation: Whys, Whens, and Hows. Endocrine
- 610 reviews. Sep 12 2024;45(5):625-654. doi:10.1210/endrev/bnae009

- 611 31. Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci,
- 612 causal insights, and heritable risk for Parkinson's disease: a meta-analysis of
- 613 genome-wide association studies. The Lancet Neurology. Dec
- 614 2019;18(12):1091-1102. doi:10.1016/s1474-4422(19)30320-5
- 615 32. Kim JJ, Vitale D, Otani DV, et al. Multi-ancestry genome-wide association
- 616 meta-analysis of Parkinson's disease. *Nature genetics*. Jan 2024;56(1):27-36.
- 617 doi:10.1038/s41588-023-01584-8
- 618 33. Wang T, Geng J, Zeng X, Han R, Huh YE, Peng J. Exploring causal effects of
- 619 sarcopenia on risk and progression of Parkinson disease by Mendelian randomization.
- 620 NPJ Parkinson's disease. Aug 28 2024;10(1):164. doi:10.1038/s41531-024-00782-3
- 621 34. Blauwendraat C, Heilbron K, Vallerga CL, et al. Parkinson's disease age at onset
- 622 genome-wide association study: Defining heritability, genetic loci, and α-synuclein
- 623 mechanisms. Movement disorders : official journal of the Movement Disorder
- 624 Society. Jun 2019;34(6):866-875. doi:10.1002/mds.27659
- 625 35. Iwaki H, Blauwendraat C, Leonard HL, et al. Genomewide association study of
- 626 Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. Movement
- 627 disorders : official journal of the Movement Disorder Society. Dec
- 628 2019;34(12):1839-1850. doi:10.1002/mds.27845
- 629 36. Krohn L, Heilbron K, Blauwendraat C, et al. Genome-wide association study of
- 630 REM sleep behavior disorder identifies polygenic risk and brain expression effects.
- 631 *Nature communications*. Dec 5 2022;13(1):7496. doi:10.1038/s41467-022-34732-5
- 632 37. Chia R, Ray A, Shah Z, et al. Genome sequence analyses identify novel risk loci
- 633 for multiple system atrophy. *Neuron*. Jul 3 2024;112(13):2142-2156.e5.
- 634 doi:10.1016/j.neuron.2024.04.002
- 635 38. Chia R, Sabir MS, Bandres-Ciga S, et al. Genome sequencing analysis identifies
- new loci associated with Lewy body dementia and provides insights into its genetic
- 637 architecture. *Nature genetics*. Mar 2021;53(3):294-303.
- 638 doi:10.1038/s41588-021-00785-3
- 639 39. Ong JS, Cuellar-Partida G, Lu Y, et al. Association of vitamin D levels and risk
- of ovarian cancer: a Mendelian randomization study. *International journal of*
- 641 epidemiology. Oct 2016;45(5):1619-1630. doi:10.1093/ije/dyw207
- 40. Lu L, Bennett DA, Millwood IY, et al. Association of vitamin D with risk of type
- 643 2 diabetes: A Mendelian randomisation study in European and Chinese adults. PLoS
- 644 *medicine*. May 2018;15(5):e1002566. doi:10.1371/journal.pmed.1002566
- 645 41. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity Analyses
- 646 for Robust Causal Inference from Mendelian Randomization Analyses with Multiple

- 647 Genetic Variants. *Epidemiology (Cambridge, Mass)*. Jan 2017;28(1):30-42.
- 648 doi:10.1097/ede.000000000000559
- 649 42. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid
- 650 instruments: effect estimation and bias detection through Egger regression.
- 651 International journal of epidemiology. Apr 2015;44(2):512-25.
- 652 doi:10.1093/ije/dyv080
- 43. Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in
- 654 Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
- 655 Estimator. *Genetic epidemiology*. May 2016;40(4):304-14. doi:10.1002/gepi.21965
- 44. Xue H, Shen X, Pan W. Constrained maximum likelihood-based Mendelian
- 657 randomization robust to both correlated and uncorrelated pleiotropic effects.
- 658 *American journal of human genetics*. Jul 1 2021;108(7):1251-1269.
- 659 doi:10.1016/j.ajhg.2021.05.014
- 45. Yu K, Chen XF, Guo J, et al. Assessment of bidirectional relationships between
- brain imaging-derived phenotypes and stroke: a Mendelian randomization study.
- 662 BMC medicine. Jul 25 2023;21(1):271. doi:10.1186/s12916-023-02982-9
- 46. Zhao J, Ming J, Hu X, Chen G, Liu J, Yang C. Bayesian weighted Mendelian
- randomization for causal inference based on summary statistics. *Bioinformatics*
- 665 (Oxford, England). Mar 1 2020;36(5):1501-1508. doi:10.1093/bioinformatics/btz749
- 47. Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal
- 667 pleiotropy in causal relationships inferred from Mendelian randomization between
- 668 complex traits and diseases. *Nature genetics*. May 2018;50(5):693-698.
- 669 doi:10.1038/s41588-018-0099-7
- 48. Pierce BL, Ahsan H, Vanderweele TJ. Power and instrument strength
- 671 requirements for Mendelian randomization studies using multiple genetic variants.
- 672 International journal of epidemiology. Jun 2011;40(3):740-52.
- 673 doi:10.1093/ije/dyq151
- 49. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between
- 675 imprecisely measured traits using GWAS summary data. PLoS genetics. Nov
- 676 2017;13(11):e1007081. doi:10.1371/journal.pgen.1007081
- 50. Evatt ML, DeLong MR, Kumari M, Auinger P, McDermott MP, Tangpricha V.
- 678 High prevalence of hypovitaminosis D status in patients with early Parkinson disease.
- 679 Archives of neurology. Mar 2011;68(3):314-9. doi:10.1001/archneurol.2011.30
- 680 51. Mayne PE, Burne THJ. Vitamin D in Synaptic Plasticity, Cognitive Function, and
- 681 Neuropsychiatric Illness. *Trends in neurosciences*. Apr 2019;42(4):293-306.
- 682 doi:10.1016/j.tins.2019.01.003

- 52. Moretti R, Morelli ME, Caruso P. Vitamin D in Neurological Diseases: A
- 684 Rationale for a Pathogenic Impact. International journal of molecular sciences. Jul 31
- 685 2018;19(8)doi:10.3390/ijms19082245
- 53. Plantone D, Primiano G, Manco C, Locci S, Servidei S, De Stefano N. Vitamin D
- 687 in Neurological Diseases. International journal of molecular sciences. Dec 21
- 688 2022;24(1)doi:10.3390/ijms24010087
- 689 54. Ndayisaba A, Halliday GM, Khurana V. Multiple System Atrophy: Pathology,
- 690 Pathogenesis, and Path Forward. Annual review of pathology. Oct 15
- 691 2024;doi:10.1146/annurev-pathmechdis-051122-104528
- 692 55. Song YJ, Lundvig DM, Huang Y, et al. p25alpha relocalizes in oligodendroglia
- 693 from myelin to cytoplasmic inclusions in multiple system atrophy. *The American*
- *journal of pathology*. Oct 2007;171(4):1291-303. doi:10.2353/ajpath.2007.070201
- 695 56. Kaji S, Maki T, Kinoshita H, et al. Pathological Endogenous α-Synuclein
- 696 Accumulation in Oligodendrocyte Precursor Cells Potentially Induces Inclusions in
- 697 Multiple System Atrophy. *Stem cell reports*. Feb 13 2018;10(2):356-365.
- 698 doi:10.1016/j.stemcr.2017.12.001
- 699 57. Ahmed Z, Asi YT, Lees AJ, Revesz T, Holton JL. Identification and
- 700 quantification of oligodendrocyte precursor cells in multiple system atrophy,
- 701 progressive supranuclear palsy and Parkinson's disease. Brain pathology (Zurich,
- 702 *Switzerland*). May 2013;23(3):263-73. doi:10.1111/j.1750-3639.2012.00637.x
- 58. May VE, Ettle B, Poehler AM, et al. α-Synuclein impairs oligodendrocyte
- 704 progenitor maturation in multiple system atrophy. *Neurobiology of aging*. Oct
- 705 2014;35(10):2357-68. doi:10.1016/j.neurobiolaging.2014.02.028
- 59. Shirazi HA, Rasouli J, Ciric B, Wei D, Rostami A, Zhang GX.
- 707 1,25-Dihydroxyvitamin D(3) suppressed experimental autoimmune encephalomyelitis
- through both immunomodulation and oligodendrocyte maturation. *Experimental and*
- 709 *molecular pathology*. Jun 2017;102(3):515-521. doi:10.1016/j.yexmp.2017.05.015
- 710 60. Gomez-Pinedo U, Cuevas JA, Benito-Martín MS, et al. Vitamin D increases
- remyelination by promoting oligodendrocyte lineage differentiation. *Brain and*
- 712 *behavior*. Jan 2020;10(1):e01498. doi:10.1002/brb3.1498
- 61. Mengozzi M, Hesketh A, Bucca G, Ghezzi P, Smith CP. Vitamins D3 and D2
- have marked but different global effects on gene expression in a rat oligodendrocyte
- 715 precursor cell line. *Molecular medicine (Cambridge, Mass)*. Apr 9 2020;26(1):32.
- 716 doi:10.1186/s10020-020-00153-7
- 717 62. Li N, Yao M, Liu J, et al. Vitamin D Promotes Remyelination by Suppressing
- 718 c-Myc and Inducing Oligodendrocyte Precursor Cell Differentiation after Traumatic

It is made available under a CC-BY-NC-ND 4.0 International license .

- 719 Spinal Cord Injury. International journal of biological sciences.
- 720 2022;18(14):5391-5404. doi:10.7150/ijbs.73673
- 721 63. Lips P, Cashman KD, Lamberg-Allardt C, et al. Current vitamin D status in
- 722 European and Middle East countries and strategies to prevent vitamin D deficiency: a
- 723 position statement of the European Calcified Tissue Society. European journal of
- 724 endocrinology. Apr 2019;180(4):P23-p54. doi:10.1530/eje-18-0736

#### Step 1: Univariable MR exploring the relationship between serum 25(OH)D levels and α-synucleinopathies

Primary analysis (Genome-wide IVs selection)							
Exposure 25(OH)D levels (417,580 participants) Outcome (1) iRBD (1,061 cases / 8,386 controls) (2) PD (5,861 cases / 494,487 controls) (3) Age at onset of PD (17,996 cases) (4) PD clinical progression (4,093 cases) (4) MSA (888 cases / 7,128 controls) (5) DLB (2,591 cases / 4,027 controls)	Selection of IVs (1) Genome-wide IVs selection: $P < 5 \times 10^{-8}$ (2) Exclude IVs closely related to the outcome ( $P < 5 \times 10^{-5}$ ) (3) LD proning: r ² > 0.001, 10000 kb (4) IVs strength: F-statistic > 10 (5) Eliminating SNPs linked to outcomes using LDtrait database	Analysis model Primary analysis model: (1) Inverse variance weighted Secondary analysis model: (1) MR Egger (2) Weighted median (3) Constrained maximum likelihood (4) MR Robust adjusted profile score (5) Bayesian Weighted MR	Sensitivity analysis (1) Heterogeneity: Cochran's Q (2) Pleiotropy: MR-Egger intercept; MR-PRESSO global test (3) Outliers: MR-PRESSO; MRradial Leave-one-out test (4) Direction: Steiger direction test; Reverse MR analysis (5) FDR correction (6) Statistical power calculation				
Replication analysis (Biological Exposure: 25(OH)D levels Outcome: PD, MSA (IVW-Pval < 0.05 in prin Biological function IVs selection: Selecting S vitamin D metabolism: GC, CYP2R1, DHCR7	function-based IVs selection) mary analysis) NPs within four key genes involved in , and CYP24A1	Replication analysis (Sunlight and vitamin D supplementation factor and α-synucleinopathies)         Exposure: Sunlight and vitamin D supplementation factors: (1) Time spent outdoors in summer, (2) time spent outdoors in winter, (3) skin colour, (4) use of sun/uv protection (5) use of vitamin D supplements, (6) no vitamin or mineral supplements         Outcome: PD, MSA (IVW-Pval < 0.05 in primary analysis)					
Exposure: 25(OH)D I Outcome: MSA (Rob Adjusted for genetic	Step 2: Multivariate MR (Ad evels ust results in primary and replication analyses pleiotropy related to features in the followi	ljusting for genetic pleiotropy)					

Set 1: Lifestyle and Socioeconomic Factors

Body mass index Smoking status •

- Alcohol intake frequency •
- Physical activity
- Years of schooling

- Alanine aminotransferase levels •
- Creatinine levels
  - ٠ Parathyroid hormone levels
- Set 3: Chronic Health Conditions
- Hypertension • •
  - Type 2 diabetes
- Atherosclerotic heart disease ٠
- Stroke
- Gastrointestinal or abdominal disease •

Exposure	Outcome	nSNPs	Method	OR (95%Cl)	Pval	Pval_fdr
Serum 25(OH)D levels	iRBD	104	IVW	→ 1.205 (0.865, 1.679)	2.71E-01	4.51E-01
			MR Egger	→ 1.048 (0.681, 1.613)	8.31E-01	
			Weighted median	→ 1.272 (0.781, 2.071)	3.34E-01	
			cML-MA	→ 1.159 (0.815, 1.649)	4.11E-01	
			MR-RAPS	→ 1.17 (0.836, 1.636)	3.60E-01	
			BWMR	→ 1.204 (0.862, 1.682)	2.77E-01	
Serum 25(OH)D levels	PD	104	IVW	0.867 (0.758, 0.991)	3.62E-02*	9.05E-02
			MR Egger	0.958 (0.803, 1.143)	6.35E-01	
			Weighted median	0.95 (0.767, 1.177)	6.40E-01	
			cML-MA	0.869 (0.749, 1.009)	6.51E-02	
			MR-RAPS	0.846 (0.735, 0.973)	1.91E-02*	
			BWMR	0.867 (0.759, 0.99)	3.51E-02*	
Serum 25(OH)D levels	PD (Age at onset)	97	IVW	→ 1.162 (0.507, 2.663)	7.22E-01	9.02E-01
			MR Egger	· 0.906 (0.313, 2.62)	8.55E-01	
			Weighted median	· 0.88 (0.267, 2.908)	8.35E-01	
			cML-MA	→ 1.122 (0.442, 2.845)	8.09E-01	
			MR-RAPS	→ 1.196 (0.509, 2.811)	6.82E-01	
			BWMR	1.154 (0.5, 2.664)	7.37E-01	
Serum 25(OH)D levels	MSA	97	IVW	0.598 (0.421, 0.851)	4.28E-03*	2.14E-02*
			MR Egger	0.522 (0.333, 0.818)	5.58E-03*	
			Weighted median	0.447 (0.273, 0.73)	1.31E-03*	
			cML-MA	0.644 (0.39, 1.062)	8.44E-02	
			MR-RAPS	0.59 (0.41, 0.848)	4.38E-03*	
			BWMR	0.597 (0.419, 0.851)	4.37E-03*	
Serum 25(OH)D levels	DLB	98	IVW	0.998 (0.777, 1.282)	9.88E-01	9.88E-01
			MR Egger	0.862 (0.623, 1.192)	3.72E-01	
			Weighted median	0.904 (0.629, 1.299)	5.86E-01	
			cML-MA	0.991 (0.761, 1.29)	9.45E-01	
			MR-RAPS	0.972 (0.751, 1.258)	8.30E-01	
			BWMR	0.998 (0.775, 1.284)	9.86E-01	
				Odds Ratio (95%CI)		



(Outcome: the risk of PD)

(Outcome: the risk of MSA)

Exposure	Covariates	Outcome	nSNPs	Method
Serum 25(OH)D levels	Body mass index	MSA	387	MVMR-IVW
				MVMR-Egger
Serum 25(OH)D levels	Smoking initiation	MSA	143	MVMR-IVW
				MVMR-Egger
Serum 25(OH)D levels	Alcohol intake frequency	MSA	138	MVMR-IVW
				MVMR-Egger
Serum 25(OH)D levels	Moderate to vigorous physical activity levels	MSA	101	MVMR-IVW
				MVMR-Egger
Serum 25(OH)D levels	Years of schooling	MSA	271	MVMR-IVW
				MVMR-Egger
Serum 25(OH)D levels	Body mass index, smoking initiation, alcohol intake frequency,	MSA	380	MVMR-IVW
	moderate to vigorous physical activity levels, and years of schoolin	ng		MVMR-Egger
Serum 25(OH)D levels	Alanine aminotransferase levels	MSA	208	MVMR-IVW
				MVMR-Egger
Serum 25(OH)D levels	Creatinine levels	MSA	305	MVMR-IVW
				MVMR-Egger
Serum 25(OH)D levels	Parathyroid hormone levels	MSA	91	MVMR-IVW
				MVMR-Egger
Serum 25(OH)D levels	Alanine aminotransferase, creatinine, and parathyroid	MSA	330	MVMR-IVW
	hormone levels			MVMR-Egger
Serum 25(OH)D levels	Hypertension	MSA	214	MVMR-IVW
				MVMR-Egger
Serum 25(OH)D levels	Type 2 diabetes	MSA	128	MVMR-IVW
				MVMR-Egger
Serum 25(OH)D levels	Atherosclerotic heart disease	MSA	95	MVMR-IVW
				MVMR-Egger
Serum 25(OH)D levels	Stroke	MSA	93	MVMR-IVW
				MVMR-Egger
Serum 25(OH)D levels	Gastrointestinal or abdominal disease	MSA	94	MVMR-IVW
				MVMR-Egger
Serum 25(OH)D levels	Hypertension, type 2 diabetes, atherosclerotic heart	MSA	227	MVMR-IVW
	disease, stroke and gastrointestinal or abdominal disease			MVMR-Egger



Pval